TerminatedNo phase
Evaluation of Effectiveness and Safety of Bioresorbable Vascular Scaffold in Routine Clinical Practice
Key facts
- Who runs it
- Duk-Woo Park, MD
- Where
- South Korea14 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- People taking part
- 629 people enrolled
- Started
- 26 Feb 2016
- Ended
- Dec 2023
- Type of study
- Observational
- Treatments tested
- Bioresorbable Vascular Scaffold
- Record updated
- 20 December 2023
- Why it stopped
- Due to stop BVS supply discontinuation
Who can take part
- Age
- 19 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Age 19 and more
- Intervention with Bioresorbable Vascular Scaffold
- Agreed with written informed consent form
Who cannot take part
- Bypass graft surgery (CABG) recommended
- Lesion with previous bypass graft surgery (CABG)
- Contraindication to antiplatelet agent or Inability to take dual antiplatelet therapy within 1 year
- Subjects scheduled to receive cardiac surgery or serious non-cardiac surgery
- Cardiac shock
- Severe calcification and/or severe tortuosity
- Life expectancy of 1year and under
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of this study is to evaluate the relative effectiveness and safety of Bioresorbable Vascular Scaffold compared to other (drug eluting stents) DES.
The group in the trial
- Bioresorbable Vascular Scaffold
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Evaluation of Effectiveness and Safety of Bioresorbable Vascular Scaffold in Routine Clinical Practice; A Multicenter, Prospective Observational Study
- Record updated
- 20 December 2023